DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forkert, P. G.
Right arrow Articles by Massey, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forkert, P. G.
Right arrow Articles by Massey, T. E.

Morphologic changes and covalent binding of 1,1-dichloroethylene in Clara and alveolar type II cells isolated from lungs of mice following in vivo administration

PG Forkert, BA Geddes, DW Birch and TE Massey

Department of Anatomy, Queen's University, Kingston, Ontario, Canada.

We have investigated the metabolism and covalent binding of 1,1- dichloroethylene (1,1-DCE) in isolated unseparated lung cells and in enriched fractions of Clara and alveolar type II cells from mice. Lung cells from control mice separated by centrifugal elutriation were viable and metabolically active as assessed by measurements of 7- ethoxycoumarin deethylase, NADPH cytochrome c reductase, and glutathione S-transferase activities, which were highest in fractions enriched in Clara cells. Mice were treated with [14C]1,1-DCE (125 mg/kg; 20 microCi/kg) in vivo and, 1 hr later, lung cells were isolated and binding of [14C]1,1-DCE determined. Covalent binding was highest in the Clara cell fraction (480 +/- 205 pmol/10(6) cells; 41% Clara cell purity) when compared to the levels present in the fractions containing type II cells (126 +/- 63 pmol/10(6) cells; 51% type II cell purity) and mixed cells from whole lung (29 +/- 13 pmol/10(6) cells). Ultrastructurally, alveolar type II cells from lungs of control and 1,1- DCE-treated mice exhibited normal morphology with well-preserved lamellar bodies. Whereas Clara cells isolated from lungs of control mice appeared structurally unimpaired, those from the lungs of 1,1-DCE- treated mice displayed severe damage and disruption of cellular organelles. The results of these experiments demonstrate the highest binding of [14C]1,1-DCE-metabolite(s) in Clara cells, whereas significantly lower binding was found in both alveolar type II and unseparated lung cells. The substantial binding of [14C]1,1-DCE in Clara cells correlated positively with the high monooxygenase capacity and the preferential damage sustained by this cell population.

Volume 18, Issue 4, pp. 534-539, 07/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
P.-G. Forkert, S. M. Boyd, and J. B. Ulreich
Pulmonary Bioactivation of 1,1-Dichloroethylene Is Associated with CYP2E1 Levels in A/J, CD-1, and C57BL/6 Mice
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1193 - 1200.
[Abstract] [Full Text]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
P.-G. Forkert
1,1-Dichloroethylene-Induced Clara Cell Damage Is Associated with In Situ Formation of the Reactive Epoxide . Immunohistochemical Detection of Its Glutathione Conjugate
Am. J. Respir. Cell Mol. Biol., June 1, 1999; 20(6): 1310 - 1318.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
T. E. Gram
Chemically Reactive Intermediates and Pulmonary Xenobiotic Toxicity
Pharmacol. Rev., December 1, 1997; 49(4): 297 - 342.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics.